Organisation › Details

Activiomics Ltd.

http://www.activiomics.com

Headquartered in London, UK, Activiomics Ltd. is a privately owned spin-out company from the Barts Cancer Institute (BCI), ranked one of the top five cancer research centres in the UK and a Queen Mary University of London campus. The company was founded in 2009 through investment from a number of sources including IP Group. Activiomics has developed a ground-breaking patented technology that will enable a transformation in the way in which biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled. Activiomics' technology centres around novel mass spectrometry based approaches for the global quantitative analysis of the proteome and of the phosphorylation status of cells and tissues. Phosphorylation is a critical mediator in all cellular processes and hence phosphorylated proteins represent an important class of novel biomarkers. Activiomics' TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology enables the quantification of thousands of phosphorylation events from a given cell or tissue sample and the subsequent markers of response that are identified will enable the development of future diagnostics. Activiomics is using exclusively accessed primary breast cancer samples to generate proof-of-concept data and high value data packages for novel predictive and prognostic markers of disease. Additionally, Activiomics commercialises its technology by partnering directly with large pharmaceutical and biotechnology companies in bespoke programmes of work. Recent partners include Genentech, UCB and GlaxoSmithKline. *

	Start	2010-03-01 splitoff (date ca.)
	Group	Retroscreen Virology (Group)
	Predecessor	Queen Mary, University of London, Institute of Cancer
	Industry	mass spectrometry technology
	Industry 2	TIQUAS technology (Targeted In-depth Quantification of cell Signalling)
	Person	FitzGerald, Kevin (Activiomics 201304– CEO F-Star 201104–201205 CEO LEFT 5/12 + Isogenica + CAT)
	Person 2	Warne, Mark (IP Group 201411 Healthcare Portfolio Director + Activiomics 201004 Interim CEO)

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	24 Cornhill
	City	EC3V 3ND London
	Tel	+44-845-5195-091
		Address record changed: 2018-07-24

Basic data	Employees	n. a.
	Currency	GBP
	Profit	-500,000 (2013-07-31)

		* Document for ï¿½About Sectionï¿½: BioFocus. (9/19/13). "Press Release: Activiomics Extends Research Agreement with Kyowa Hakko Kirin as Part of Its Strategic Partnership with BioFocus".

		Record changed: 2019-06-09

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Associations

Advertise

Activiomics Ltd.

More documents for Retroscreen Virology (Group)